Contrasting Whitehawk Therapeutics (NASDAQ:WHWK) & BetterLife Pharma (OTCMKTS:PVOTF)

BetterLife Pharma (OTCMKTS:PVOTF) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares BetterLife Pharma and Whitehawk Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BetterLife Pharma	N/A	N/A	-$14.78 million	N/A	N/A
Whitehawk Therapeutics	$25.98 million	4.70	-$63.69 million	$0.14	18.50

BetterLife Pharma has higher earnings, but lower revenue than Whitehawk Therapeutics.

Institutional and Insider Ownership

52.1% of Whitehawk Therapeutics shares are held by institutional investors. 34.8% of BetterLife Pharma shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares BetterLife Pharma and Whitehawk Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BetterLife Pharma	N/A	-205.15%	-147.23%
Whitehawk Therapeutics	99.42%	-68.32%	-63.21%

Analyst Recommendations

This is a summary of current ratings for BetterLife Pharma and Whitehawk Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BetterLife Pharma	0	0	0	0	0.00
Whitehawk Therapeutics	1	1	0	0	1.50

Given BetterLife Pharma’s higher possible upside, equities research analysts clearly believe BetterLife Pharma is more favorable than Whitehawk Therapeutics.

Summary

Whitehawk Therapeutics beats BetterLife Pharma on 8 of the 10 factors compared between the two stocks.

About BetterLife Pharma

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.